News | August 24, 2023
Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ
The company has entered into a three-year Deferred Prosecution Agreement
The company has entered into a three-year Deferred Prosecution Agreement
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
The company has 47 ANDA's pending approval with the U.S.FDA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)